<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861884</url>
  </required_header>
  <id_info>
    <org_study_id>18NS001</org_study_id>
    <nct_id>NCT03861884</nct_id>
  </id_info>
  <brief_title>Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)</brief_title>
  <official_title>Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nottingham University Hospitals NHS Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study aims:

        1. to compare cognitive performance in different clinical groups of participants with mild
           cognitive impairment (MCI) or mild dementia [Alzheimer's Disease (AD), Vascular
           Cognitive Impairment (VCI) and Fronto-temporal Dementia (FTD)] to determine whether
           scores reveal differential profiles between the groups,

        2. to demonstrate differences in imaging markers between different dementia syndromes and
           healthy volunteers using ultra high-field MRI at 7T.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The imaging arm of the study include:

        1. to demonstrate differences in brain iron levels between different dementia syndromes and
           healthy volunteers using ultra high-field MRI, quantitative susceptibility mapping (QSM)
           at 7T.

        2. to demonstrate variations in the resting oxygen usage as an important biomarker to
           discriminate between different dementia syndromes.

        3. to demonstrate cerebral blood flow changes in the brain, particularly in the hippocampus
           region, and its correlation with different dementia syndromes using Arterial Spin
           Labelling MRI technique.

        4. to demonstrate increased blood brain barrier leakage in the brain, particularly in the
           hippocampus region, and its correlation with Alzheimer's Disease (AD) and Vascular
           Cognitive Impairment (VCI) using a new dynamic contrast-enhanced MRI (DCE-MRI)
           technique.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive scales on Birmingham Cognitive Screen (BCoS) Scores</measure>
    <time_frame>Through study completion (an average of one year)</time_frame>
    <description>cognitive sub scores in relation to clinical phenotype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Structural imaging changes on MRI at 3T</measure>
    <time_frame>Through study completion (an average of one year)</time_frame>
    <description>Structural volume loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Susceptibility weighted mapping at 7T</measure>
    <time_frame>Through study completion (an average of one year)</time_frame>
    <description>Quantitative Susceptibility Mapping</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Dementia (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Cognitive assessments</arm_group_label>
    <description>Neurocognitive assessments, Birmingham Cognitive Screen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI at 3T</arm_group_label>
    <description>Brain Imaging: MRI at 3T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI at 7T</arm_group_label>
    <description>Brain imaging: Ultrahigh Field MRI at 7T</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cognitive assessments</intervention_name>
    <description>Cognitive assessment and MRI at 3T and/or 7T</description>
    <arm_group_label>MRI at 3T</arm_group_label>
    <arm_group_label>MRI at 7T</arm_group_label>
    <other_name>MRI at 3T</other_name>
    <other_name>MRI at 7T</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Alzheimer's disease, Frontotemporal dementia, Vascular Cognitive Impairment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to give informed consent.

          2. Either pathological, genetic or imaging biomarker evidence to suggest Fronto-temporal
             Lobar Degeneration, Alzheimer's Disease or Vascular Cognitive Impairment, or defined
             clinical diagnoses.

        Exclusion Criteria:

          1. Lack of mental capacity to consent to study involvement.

          2. Not speaking English before age 5 years.

          3. Learning disability.

          4. MRI contraindications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akram Hosseini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akram.Hosseini@nuh.nhs.uk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akram Dr Hosseini</last_name>
    <phone>0115 924 9924</phone>
    <phone_ext>66410</phone_ext>
    <email>Akram.Hosseini@nuh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pauline Hyman-Taylor</last_name>
    <phone>0115 924 9924</phone>
    <phone_ext>60677</phone_ext>
    <email>pauline.hyman-taylor@nuh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nottinghamshire Healthcare NHS Foundation Trust</name>
      <address>
        <city>Nottingham</city>
        <state>Easat Midland</state>
        <zip>NG7 2TU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clare Litherland</last_name>
      <email>Clare.Litherland@nottshc.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Craig Beecroft</last_name>
      <email>Craig.Beecroft@nottshc.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>East Midland</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Wilkins</last_name>
      <email>Sara.Wilkins@nuh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Julie Lynch</last_name>
      <email>Julie.Lynch@nuh.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

